One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...
The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...
Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Over the next decade, modern medicine is poised to undergo a redefinition that has not been seen in generations. The surge in innovation, transformational scientific discoveries and rapidly maturing technologies is redefining patient outcomes. The biotech industry is...
Did you know that your body has its own biological process for clearing out old or damaged cells, and recycling dysfunctional components to prioritize healthier, more productive ones? For billions of years, autophagy has acted as a kind of evolutionary survival...
The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report...
As the echoes of the COVID-19 crisis fade, humanity remains on high alert for the inevitable next pathogen. What if we could dissect viruses down to their atomic core, revealing chinks in their armor that lead to revolutionary treatments? Drawing from my 12+ years as...
The life sciences sector is experiencing a fundamental reshaping of its innovation geography as funding pressures, policy shifts, and geopolitical tensions redraw the competitive landscape across continents. While research funding constraints in the United States...
Marking its success San Diego debut earlier this month, Phacilitate’s Advanced Therapies Week (ATW), brought together leaders, innovators, and industry stakeholders from around the world for a dynamic showcase of progress in cell and gene therapies (CGT). From...
Kelly Nguyen is a molecular biologist and Group Leader in the Structural Studies Division at the MRC Laboratory of Molecular Biology (LMB), where her research aims to uncover how telomeres are structured, maintained and regulated by the enzyme telomerase. Telomeres...
In the pharmaceutical industry, the statistics of failure are so familiar they have become clichés: it takes ten years and two billion dollars to bring a new drug to market, with a failure rate in clinical trials hovering near 90%. While much of this attrition is...
After decades of promise and setbacks, advanced manufacturing platforms and robust Phase 2/3 trials are demonstrating whether MSCs can deliver transformative treatments for high-burden diseases Mesenchymal stromal cells (MSCs) have been called the most promising...
Generative AI has already changed what is possible in protein engineering. In the last few years, the field has moved from predicting protein structures to proposing entirely new proteins, often with experimentally verified folding and binding, at a pace that was...
Antibiotics are one of the greatest success stories in modern medicine. They transformed once-deadly infections into treatable illnesses, made routine surgery possible, and helped extend human life expectancy worldwide. From treating pneumonia to protecting patients...
“Hypoxia” used to be nothing but a niche biology topic. Today it is quietly becoming standard infrastructure in labs. Two forces are converging. Regulators and funders are nudging R&D away from default animal studies and toward human-relevant evidence. At the...